|Bid||41.44 x 900|
|Ask||41.56 x 900|
|Day's Range||40.36 - 41.68|
|52 Week Range||20.03 - 50.26|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 05, 2021 - May 10, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||63.89|
With us are Ken Mills, REGENXBIO's President and Chief Executive Officer, Dr. Steve Pakola, our Chief Medical Officer, Dr. Olivier Danos our Chief Scientific Officer, and Vit Vasista, our Chief Financial Officer. Earlier this afternoon, REGENXBIO released financial and operating results for the fourth quarter and full year ended December 31, 2020.
Regenxbio (RGNX) delivered earnings and revenue surprises of -211.71% and -83.48%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Regenxbio (NASDAQ:RGNX) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 72.22% over the past year to ($1.24), which missed the estimate of ($0.43). Revenue of $21,445,000 rose by 82.23% year over year, which missed the estimate of $61,500,000. Outlook Earnings guidance hasn't been issued by the company for now. Regenxbio hasn't issued any revenue guidance for the time being. How To Listen To The Conference Call Date: Mar 01, 2021 View more earnings on RGNX Time: 04:30 PM ET Webcast URL: https://edge.media-server.com/mmc/p/wux4dg9b Technicals 52-week high: $50.26 52-week low: $20.03 Price action over last quarter: Up 46.54% Company Overview Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). See more from BenzingaClick here for options trades from BenzingaEarnings Scheduled For March 1, 2021© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.